• Fan Pass creates the streaming space for artists to gain revenue, go live, and build their fanbase
• Friendable is currently in the beta phase version 2 for the mobile and desk application of the Fan Pass platform, which will feature a new design, technology advancements, backstage VIP access, and scalable social media
• The updated version is expected to become available as early as June 2021
• The global music streaming market is expected to grow exponentially, from $20.9 billion in 2019 to $76.9 billion by 2027

Friendable (OTC: FDBL) announced another record month of growth for its Fan Pass platform, which reported 1,236% of live artist channel growth over March 2021. The increase comes as the company announced that it has entered beta phase version 2 of the Fan Pass mobile and desktop application, featuring an all-new design, technological advancements, backstage VIP access, and scalable social media. These enhancements will benefit both the fans and the artists who use the platform (https://ibn.fm/qRZc8). At the end of March 2021, 22 live artist channels across various musical genres were completed on the Fan Pass platform. With the number of live performances doubling from the month prior, April was the month that Friendable had expected a significant ramp-up of new live artist channel activation on Fan Pass. The success of the deployed technology and dashboard upgrades have allowed the company to use some of these new features to advance live channels before fully releasing version 2 of the platform. Friendable anticipates that version 2 will be available in early June 2021. “With entirely new and updated technologies, UI, UX designs, and general interactions and enhancements made on the platform, our team is extremely excited about rolling out version 2 of Fan Pass to our current artists, new artists, and their fans,” CEO Robert A. Rositano said. Since its launch in July 2020, Fan Pass has been growing steadily, positioning itself as a unique avenue for enhanced interaction and engagement between artists and fans in a fully safe, online environment. Always committed to service artists and fans, the team behind Fan Pass has been gathering user feedback about the platform and hopes version 2 will address all issues while exceeding collective expectations. Fan Pass was designed to give artists a virtual stage, allowing them to earn money while increasing their fan base. The new v2 enhancements will allow for quicker artist onboarding and better navigation of the platform. Artists get to: Create New Revenue

• Artists get paid for live or PPV events
• 100% of ticket sales go to the artist (less any fees for an agency, agent, manager, etc. if applicable)
• Gain a share of the monthly subscription revenue based on “content views” generated by all Fan Pass fans across the platform

Build a Fanbase

• Artists upload content to the platform, keeping their fans engaged
• Fan Pass has all the promotions that an artist could need – merchandising, marketing, etc.

Go Live – with Livestreaming

• Artists sell tickets to live performances and events streamed in the highest quality available right to the fans’ phone or computer – all an artist has to do is notify they are going live, and fans stay in the loop!

Fan Pass also offers a Pro Services option, which covers everything from graphic design to marketing to merchandising. Services start at $90 (currently $45 with the promotional pricing) for a Basic Marketing Materials Package and increase to $1000 (currently $500 with the promotional pricing) for the customized Merch Collection. Fan Pass Pro Services is one of the many perks that artists joining the platform have access to. With its livestreaming services and options, Friendable is well positioned to become a top platform of choice for musicians and fans alike due to the opportunities for continued engagement and revenue generation, earning Fan Pass a prominent role in the fast-growing global music streaming market. In 2019, before the pandemic, the music streaming sector was valued at $20.9 billion, but it expected to expand at a CAGR of 17.8 percent and reach $76.9 billion by 2027, amid growing interest in music streaming services (https://ibn.fm/3YTiV). For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• The name Sonoma is analogous with not only wine country but diversified agriculture, and now ultra-premium cannabis
• High-end consumers are seeking out place-based designations that they trust and they willing to pay a premium
• Investors are turning to companies like Sonoma Biologics, who have already established themselves within the competitive California market and have shown themselves capable of scaling up quickly without compromising on product

Sonoma Biologics, an ultra-premium cannabis grower focused on the medicinal and recreational cannabis markets, is on a mission to become one of the largest organic-equivalent, environmentally friendly cannabis suppliers in northern California. The Company utilizes solar energy and is on the path to becoming a certified comparable-to-organic cannabis grower through the OCal program, a statewide certification comparable to the National Organic Program. While California growers are scrambling to keep up with the trends of 2021, Sonoma Biologics has already established itself (https://ibn.fm/Hvsp7). “We see cannabis being grown in wine country the same way we see Napa and Sonoma grapes being accepted all over the world,” says Paul Caracciolo, Sonoma’s CEO & Co-Founder. “The name Sonoma to me is analogous, not only with wine country, but also with broad diversified agriculture.” The area is already well known for its exquisite vineyards and the wine they produce. Sonoma county has also established itself as a leader in organic produce and sustainable farming.  High-end and organic-conscious consumers seek out place-based designations for their products in the same way that wine connoisseurs turn to Sonoma for the highest quality of wine. Anticipating price fluctuation in the market, evolving taxes and difficulty with quality compliance and California regulations, turnover of cannabis businesses is expected in Q3 of 2021 and on. Investors are turning to companies that have already established themselves within the competitive market and have shown themselves capable of scaling up quickly without compromising on product. Consumers in 2021 are seeking out products that are naturally sun-grown, as opposed to greenhouse and warehouse growth. They are seeking out place-based designations that hold quality certifications. Currently, consumers are willing to pay premium for these products, and California is working to formalize appellations. “Participating in the CDFA, the California Department of Food and Agriculture, will ensure that customers who see the Sonoma designation on a product label, will instantly understand they are getting the highest quality, sun-grown, natural, pure product,” says Caracciolo (https://ibn.fm/CwoxV). The team at Sonoma Biologics strongly believes that sun-grown cannabis has different concentrations of terpenes and qualities you won’t find in products grown indoors under artificial light. With multiple outdoor growing locations situated in the heart of California’s wine country, the Company is capable of large-scale, ultra-low-cost production. Management has been in the large-scale agriculture business for the last decade in Sonoma and entered into cannabis in the previous three years. Having passed stringent California quality control regulations for cannabis since beginning, they continue to provide a high-quality, sun-grown, natural, sustainable, pure, and consistent product. “Our approach is being consistent and finding things that work and sticking to them,” says Caracciolo. “If you look across the crop that we have, all the plants are exactly the same size. It’s the way that you treat them, it’s the spacing, it’s the nutrition you give them.” For more information, visit the company’s website at www.OwnSonomaBiologics.com. NOTE TO INVESTORS: The latest news and updates relating to Sonoma are available in the company’s newsroom at https://ibn.fm/Sonoma

• Catalog features musical tracks from A-list celebrity musical artists including Beyonce, Justin Timberlake, Demi Lovato, Cher, and more
• NFTs are hosted on Ethereum blockchain with potential trading on OpenSea
• Three royalty pools available for staking: publishing, mechanical/public performance, and synchronization, and tokens will be available in addition to these pools
• Stakers have the opportunity to earn four different ways with the BAND NFTs, but royalties are not a guarantee
• The market has exploded coming into 2021 due to the increased exposure of NFTs, especially after Twitter CEO Jack Dorsey’s sale of his first tweet for $2.9 million

Operated by Singapore-based LIBERTY IS PTE LTD, BAND Royalty is an entertainment technology-driven firm focused on distributing non-fungible tokens (“NFTs”) that allow fans to earn royalties from top songs and artists worldwide. Fans get to take their enjoyment of music to the next level through BAND Royalty NFTs that enable holders to earn crypto from some of the world’s most popular songs. The unique opportunity allows individuals to share income streams each time a song in the NFT catalog is performed. The pool of BAND’s NFTs leverage a performance catalog that features musical tracks from A-list musicians, including Beyonce, Justin Timberlake, Demi Lovato, Cher, and more, earning royalties every time the catalog is played (https://ibn.fm/hfYT8). The NFTs are hosted on the Ethereum blockchain, with owners of the NFTs being able to trade them on one of the largest NFT marketplaces – OpenSea. The revenue generated from the BAND music royalty catalog is not guaranteed, much like revenues for market investments cannot be guaranteed. Stakes in the three BAND music royalty pools can range from 90 days to five years once the smart contracts open up at the beginning of Q3 in July 2021. All holders of BAND NFTs during Q2 will automatically qualify for royalty payments in Q2, provided that they stake immediately upon the opening of the royalty pool smart contract. The royalty pools available for staking include 1) publishing, 2) mechanical/public performance, and 3) synchronization. A share in the royalty pools is only available for those who stake BAND NFTs, and staking does not equal ownership of royalties but provides access to income from the various royalty streams. BAND NFT stakers earn four ways:

1. Earning 50% from all BAND Royalty music catalog revenue.
2. Earning 5% on BAND NFTs traded on OpenSea or the BAND platform.
3. Earning 50% from any auctions of single BAND music tracks sold.
4. Earning 5% from reselling music royalties on the band platform.

BAND Royalty plans on four limited-edition NFT series that will include 3,000 NFTs plus a standard fungible BAND token and BAND app. BAND will issue a total of up to 12,000 NFTs, designed to be stand-alone collector items that provide collectible value – something not seen in other NFTs to date. The first limited-edition NFTs will be launched on May 5, ,2021, followed by the second NFT series in June and a third in August, with various events occurring concurrently. The market for NFTs has taken off exponentially in 2021 due to a rise in media coverage and mainstream awareness. An example of a recent NFT is the first tweet ever sent by Jack Dorsey, the CEO of Twitter and Square. Dorsey sold this tweet as an NFT for over $2.9 million in March 2021 (https://ibn.fm/avJGF). Other instances of higher-profile NFT sales include the “Everyday: The First 5000 Days”, a digital art piece by artist Beeple that sold for $69.3 million at Christie’s, and a music video by digital artist Slime Sunday and 3LAU that sold for $1.3 million, with the buyer winning the opportunity to name the song (https://ibn.fm/Z8Qte). Founded by Barnaby Andersun (“BA”) and Noble Drakoln (“ND”), who leverage years of experience in blockchain, e-commerce, and music royalties, BAND Royalty is uniquely positioned to capitalize on the shifting landscape surrounding digital ownership as it launches its NFT offering. For more information, visit the company’s website at www.BANDRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND Royalty are available in the company’s newsroom at https://ibn.fm/BAND

• XPhyto Therapeutics Corp. recently announced it has entered into a distribution, storage and logistics agreement with a German distributor with an established network throughout Germany
• Germany holds promise due to regulations requiring mandatory weekly testing for its citizens; this has the possibility of ramping up sales
• Anticipating the increase in sales and distribution, XPhyto expanded its commercial leadership team by bringing on board Mr. Wolfgang Probst and Mr. Manfred Buchberger
• Mr. Probst will be the company’s Chief Operations Officer (“COO”), while Mr. Buchberger will be the Head of Corporate Development at wholly owned subsidiary XP Diagnostics GmbH

The approvals XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) received in Europe back in March for the commercial production and use of its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) (https://ibn.fm/VwPeW), set the ball rolling for events that would lead to a recent announcement. On April 21, XPhyto, a life sciences technology accelerator, announced it has entered into a distribution, storage and logistics agreement with a full-fledged German pharmaceutical wholesaler and service provider, which will back the company’s efforts to launch sales in April (https://ibn.fm/65aYL). The German distributor will distribute, store, and deliver the Covid-ID Lab test kits to XPhyto’s customers in line with the relevant logistical and regulatory requirements in Germany and the product specifications. In addition, the agreement stipulates that the distributor fulfills storage, reporting and notification obligations, processes any product returned by buyers and provides documentation. With the agreement, XPhyto CEO and Director Hugh Rogers noted that the company had secured a strong partner with an already established network in Germany. “The company’s commercialization strategy is focused on the German market for initial product launch and the creation of robust and sustainable sales,” he added. Germany shows promise as a market that will ramp up XPhyto’s sales revenue. The slowed vaccination rollout in the country has meant that testing requirements have persisted. In fact, in late March, the government made it mandatory for workers employed in sectors where physical contact with customers is inevitable to take at least two rapid tests weekly (https://ibn.fm/EWjuk). The new regulations also mandated every person to conduct a point-of-care test before attending a private or public event (https://ibn.fm/cTE6B). These regulatory changes came barely a month since the country experienced shortages in rapid test kits following a steep spike in demand during the first week of March. This rise in demand was occasioned by the German government’s reliance on rapid tests to steer the country through the pandemic and assuage the citizens’ displeasure at the prevailing COVID-19 lockdowns at the time. Beginning the second week of March, every German citizen would be entitled to a single free rapid test every week, to be conducted by a professional at designated testing centers or pharmacies (https://ibn.fm/uYHtJ). Combined, these regulatory requirements show that the conditions are favorable for XPhyto to witness sustainable sales, particularly with the inking of the distribution deal. Anticipating this rise in sales, the company made additions to its leadership team, focusing on the commercial aspect of the business (https://ibn.fm/9UuBL). In a recent announcement, XPhyto reported that it had appointed Mr. Wolfgang Probst as its Chief Operations Officer (“COO”) and Mr. Manfred Buchberger as the Head of Corporate Development at XP Diagnostics GmbH, XPhyto’s wholly owned German subsidiary. Both Mr. Probst and Mr. Buchberger bring a wealth of experience to their new positions. Mr. Probst, a seasoned management and finance consultant with a proven track record of organizational restructuring, strategic planning and leadership, is credited with restructuring XPhyto’s operations in Europe, as well as spearheading partnerships with institutions and other companies. He will be in charge of the company’s global operations and remain the XP Diagnostics MD and an XPhyto director. Mr. Buchberger, a global leader in the medical diagnostics industry, has near ten years’ experience as a CEO and member of the Global Management Board of a leading medical diagnostics and analytics company based in Europe. He is accredited with launching new medical diagnostic products, as well as creating, effecting and managing business growth strategies across four continents. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• Retail chain store projected to generate estimated $10M annually
• Company CEO calls acquisition “transformative”
• Retail is valued resource for GLH development of product lines, execution on brand messaging

Golden Leaf Holdings (CSE: GLH) (OTCQB: GLDFF), a proven, consumer-driven cannabis company in both the medicinal and recreational marijuana market segments, has signed a letter of intent (“LOI”) to acquire a retail chain in Northwest Oregon, which is forecast to generate an estimated $10 million in annual run rate revenue (https://ibn.fm/dRY8o). “The acquisition of this retail chain will be transformative for GLH, as it would further cement us as a leader in the Oregon market,” said Golden Leaf CEO Jeff Yapp. “The company expects this transaction to be accretive on close, as we will achieve tremendous synergy with our effort and current footprint and the introduction of our market-leading Chalice brand products.” Golden Leaf plans on providing additional details about the transaction once a definitive purchase agreement has been completed. The strategic move aligns with Golden Leaf’s focus on retail, which the company feels is a dynamic and effective tool to truly understand the current state of the marketplace. Golden Leaf looks to its seven Chalice Farms retail stores located throughout the Portland area as invaluable resources for instant customer feedback. “Our retail stores provide a daily report as to what products are working best and what needs improvement,” the company states. “[Retail] gives us first-hand information about what’s trending in the market and what people are asking for. Retail is a valued resource for our development of product lines and executing on brand messaging.” From the opening of its first Chalice Farms dispensary, the company has been committed to creating a different experience for consumers. Each location is inviting and warm, with an approach similar to the Apple store model, with products featured on island stations located throughout the store. The design is intended to invite interaction and connection between Chalice Farms personnel and consumers, creating an open atmosphere where questions can be asked, information can be exchanged, and a positive experience will be enjoyed. Key to that positive experience are Chalice Farms product specialists, who are highly trained in all the products offered at each retail location. Golden Leaf provides ongoing training and education to ensure these friendly company representatives have information necessary to assist a broad range of consumers, from the first-time visitors to the high-end connoisseurs. With a wide array of products that are often updated, informed product specialists are essential to the five-star consumer experience that Golden Leaf is committed to provide. For more information, visit the company’s website at www.GoldenLeafHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to GLDFF are available in the company’s newsroom at https://ibn.fm/GLDFF

• Definition of craft spirits differs widely from distillery to consumer
• SBEV’s SALT Tequila strives to stand out among tequila crowd
• SALT Naturally Flavored Tequila is 100% Blue Agave, 80 proof
• Careful attention to detail results in mellow, sweet, fully developed agave flavor unmatched in industry

The definition of craft distillery varies throughout the industry; in fact, the American Craft Spirits Association (“ACSA”) has decided not to define craft but allow its members and consumers to ultimately determine their own definition (https://ibn.fm/iKQzn). Splash Beverage Group (OTCQB: SBEV), a holding company of leading portfolio of beverage brands, has defined the term with its one-of-a-kind SALT Tequila (https://ibn.fm/2Mk1J). Although the ACSA accepts that the term “craft” is in the eye of the beholder, the association notes that it thinks of craft spirits as “a product produced by a distillery who values the importance of transparency in distilling, and remains forthcoming regarding the spirit’s ingredients, distilling location, and aging and bottling process.” Splash Beverages does all of this and more through the creation of its proprietary SALT Tequila. Splash notes that its unique tequila offering relies on the focus and dedication of a boutique distillery, the skill and expertise of a tequila master, and experts trained in the art and craft of tequila. The result? The first and only tequila crafted to be enjoyed as a drink—best neat or over ice. And no wonder the beverage stands out in the tequila crowd. Each bottle of SALT Tequila is made from handpicked, 100% pure blue agave plants grown in the mountains of Jalisco. The area is one of the Mexico’s most fertile agave-growing regions, and each agave plant grows seven to 10 years before being harvested. Such attention to detail results in a mellow, sweet, fully developed agave flavor unmatched in the industry. In short, SBEV’s SALT Tequila represents years of deliberate determination, inspiring innovation, and invaluable expertise culminating together in the clear, smooth, sweet and natural flavor that has come to define one of the industry’s finest tequila offerings. Specializing in manufacturing, distributing, sales and marketing of various beverages across multiple channels, Splash operates in both the alcoholic and nonalcoholic beverage segments, allowing it to leverage efficiencies and dilute risk. The company’s business strategy is to quickly develop and accelerate pre-existing brands to exit for cash events. The company’s management team has invaluable expertise and insight, and the company strives to identify brands it perceives to have highly visible preexisting brand awareness or pure category innovation. Specifically, the company look for brands and products that are on trend and deliver natural quality, health benefits, freshness and refreshment within their beverages. The company looks to maintain highest performance standards and focus on execution as it works with distributors and retail partners to achieve and exceed all goals. In addition, the company offers support for members of the U.S. armed forces, first responders and health-care professionals. For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

• FingerMotion has forged strong relationships with the three largest telecommunication companies in China
• The relationships have given FNGR access to subscriber data, allowing it to test its proprietary data analytics algorithms in real-time
• The algorithms, created by FingerMotion’s Big Data Insights Division, leverage raw mobile data to create a user persona

A technological company, FingerMotion (OTCQX: FNGR) has evolved over the years. What began as a mobile gaming company, launched in 2016, morphed into a mobile payment and recharge service provider in 2018, offering these services to China Unicom’s (NYSE: CHU) customers. That same year, FNGR was awarded a contract to become CHU’s big data analysis partner, with success from this agreement leading to a similar arrangement with China Mobile the following year. In 2019, the company began offering mobile payment and recharge services to the users of both China Mobile and China Telecom (NYSE: CHA). “We began by forging relationships with the three telecoms in China, China Telecom, China Mobile and China Unicom. By building up our relationships and providing consistent and dependable service, they have, in turn, given us unprecedented access to their respective user bases. This allows us to target telecom users with innovative products in an unobtrusive manner,” FingerMotion CEO Martin Shen said in a presentation during the Emerging Growth Conference (https://ibn.fm/Bc3iN). The relationships with the three telecommunication companies, whose combined subscriber base as of 2020 stood at over 1.5 billion users (https://ibn.fm/YpyFF), helped FingerMotion venture into the big data insights business. Shen, who described the company’s Big Data Insights division as the most exciting, noted in a separate webinar address (https://ibn.fm/eX8TW) that this division comprises a team of data scientists and actuaries who have developed proprietary algorithms to predict human behavior. FNGR then leverages its relationship with the telecommunication juggernauts to run these algorithms in real-time and off a secure database. “We’re well-positioned to capitalize on the continually growing power of mobile data, transforming telecommunication signals into data blocks and integrating them with a host of external data and auxiliary information for mining and analyzing behavioral insights,” Shen added. According to Shen, the company aims to create an integrated data ecosystem through technology and innovation. To do this, it intends to start with offering enhanced efficiency and user experience in mobile communications and subsequently extend the scope to deeper consumer behavior analytics, anchored on a comprehensive set of high quality and relevant mobile user data. This approach will enable the company to meet the needs of its customers through products and partnerships. FingerMotion, which intends to ultimately offer products for the insurance, healthcare and finance sectors, is initially focusing on insuratech. This focus was evident in January when the company announced it has partnered with Pacific Life Re-insurance, in effect becoming its data provider. Notably, the partnership will extend beyond simply providing data as FNGR will also offer behavioral analytics, which Shen described as “brief insights into human nature itself.” To generate the data insights, FingerMotion’s algorithm will rely on raw mobile data, including rudimentary information such as age, gender and place of residence. The algorithm will overlay this basic tier with a person’s geospatial information, such as places they have visited, to learn about the person and what they do throughout the day. Finally, it will utilize the individual’s internet usage, as well as call and SMS data. However, it’s important to remember in all of this that the personal information is scrubbed, and only demographic information is used to create the data packets that personify the mobile data. By superimposing the four tiers, the algorithm can create anonymous data packets that personify the mobile data, describing the phone usage with parameters such as their occupation, number of hours they work, fitness level and more. FingerMotion is clearly leveraging raw mobile data to offer a big data asset that can significantly help companies. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Pharmaceutical developer Tryp Therapeutics is targeting orphan disorders with novel medicinal solutions
• The company’s initial candidates seeking regulatory approval are a psilocybin compound for treating fibromyalgia, eating disorders and chronic pain conditions, as well as a tumor-inhibiting drug for treating soft tissue sarcomas
• Tryp has partnered with the University of Florida to conduct a Phase 2a clinical trial for eating disorders using Tryp’s psilocybin product

Following a year in which a global pandemic led to heightened concerns about individuals’ mental well-being while navigating the health emergency’s effects on society (https://ibn.fm/YGqDb), proponents of psychedelic medicine development programs gained stronger allies in legislative as well as commercial arenas (https://ibn.fm/sUosF).

Pharmaceutical developer Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is making its own inroads with using psychedelics for medicinal purposes, conducting clinical trials in preparation for planned monetization of its two drug platforms — the mushroom-based psychedelic compound, psilocybin, for treating fibromyalgia, eating disorders and chronic pain conditions, and the cancerous tumor-inhibiting drug razoxane for treating soft tissue sarcomas.

Tryp was founded in 2019 and recently released its Q2 interim financial results for the three and six month periods ended February 28, 2021, showing completion of the company’s initial public offering (“IPO”) that brought in more than $5 million through the aggregate issuance of more than 20 million units in December (https://ibn.fm/yHsVj).

During the reporting period, Tryp also added three leading experts to its Scientific Advisory Board and named a new CEO and a new CFO. The report also noted advancements with Tryp’s synthetic psilocybin manufacturing program and a new collaboration with the University of Florida on clinical trial activities for eating disorders.

A series of reports and studies indicate that the pandemic has likely fueled a rise in problems associated with eating disorders, including one finding that there has been a 70 percent rise in mental health support referrals for eating disorders among youth during the pandemic (https://ibn.fm/nI4Gb). Two new studies found a correlation between the COVID-19 pandemic and post-traumatic stress disorder (“PTSD”) symptoms among patients with eating disorders (https://ibn.fm/EEbEp).

Pediatric physician Jennifer Miller, M.D. of the University of Florida is serving as the principal investigator for a Phase 2a clinical trial for eating disorders using Tryp’s psilocybin product.  Dr. Miller is a leading expert in certain eating disorders including binge eating and hyperphagia.  The clinical trial that she is leading is expected to significantly advance Tryp’s work in evaluating the safety, pharmacokinetics and efficacy of TRP-8802, Tryp’s key product under its Psilocybin-for-Neuropsychiatric Disorders (PFN(TM)) program.

“There are currently no approved drugs and only limited options to treat patients with rare over-eating disorders,” Miller stated in a news release announcing the collaboration (https://ibn.fm/8jecT). “I’m excited to work with the Tryp team to explore the use of psilocybin as a new paradigm to treat symptoms associated with this devastating medical disease.”

In the end, Tryp’s aim is to develop clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways. A provisional patent filed in March 2021 establishes the company’s IP for the formulation, delivery and dosing of psychedelics to produce a potential reduction in the time spent by patients in the dissociative state, and Tryp plans to submit additional provisional patents this year related to the manufacturing and formulating of psilocybin, among other innovations.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• RYAH Group to start trading on Canadian Securities Exchange following a transaction involving a triangular merger
• RYAH Group is digital health care analytics and technology company developing innovative solutions for the plant-based medical industry
• RYAH is poised for growth as the world transitions to remote health at an accelerated pace due to the pandemic

RYAH Group (formerly known as Prime Blockchain Inc.) will start trading on the Canadian Securities Exchange under the ticker symbol “RYAH” today (https://ibn.fm/Z6gZj). The New York-based digital health care analytics and technology company is focused on the development and commercialization of innovative technology, including software and hardware, for the plant-based medical industry. The upcoming listing follows the Company’s previously announced closing of a reverse takeover transaction with Potbotics Inc. The transaction included a triangular merger between RYAH Group (formerly Prime Blockchain, Inc.), Potbotics, and a wholly-owned Florida subsidiary of the Company incorporated to complete the transaction (https://ibn.fm/EhuYh). For companies making a public market debut, traditional IPOs were dominant until 2019, but novel forms of going public stole the limelight in 2020. This includes reverse mergers, a transaction where a private company buys out shares to control the public company. The two entities merge, which effectively makes the private company become public (https://ibn.fm/vA0wf). “This is another major step in our journey in transforming patient care through our remote, connected devices and data analytics, to help unearth breakthrough discoveries that will reshape our understanding of plant-based medicines, nutraceuticals and beyond. We continue to live our mission and vision of delivering cutting-edge innovation to advance digital care and to provide shareholder and consumer value in all of our products and services,” said Gregory Wagner, CEO of RYAH Group Inc. As an emerging company, RYAH Group Inc. has been committed to leveraging its know-how in predictive analytics to establish itself as a leader in delivering innovative, user-friendly IoT devices in the plant-based medical industry. The Company applies novel AI-powered analytics to pioneer a suite of vertically integrated technologies to facilitate data collection across the medical plant lifecycle, offering users added control over their health and wellness. RYAH Group Inc’s powerful artificial intelligence platform collects and correlates HIPAA-compliant medical data to assist doctors and patients in personalizing therapeutic treatments to better predict treatment outcomes. The data aggregation is also relevant for research institutions, pharmacies, clinics, growers, dispensaries and licensed processors to monitor and manage plant-based medicine and other formulation effects on patients. RYAH Group Inc’s commitment to advance the transition to remote digital care and data analytics in patient treatments appears to be well-timed. The last year saw the world shifts to everything online — health care included. With so many growth opportunities opened up due to the pandemic, the Company appears poised to solidify its position in the digital health care analytics market with the upcoming listing. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• As vaccine rollout continues nationwide, pent-up demand is expected to burst, fueled by massive reserves of excess savings
• Economists expect record consumer spending over the next two quarters, at levels not seen in the past 70 years
• SHRG seizes lucrative market opportunities, leverages business model to enter the travel sector

Sharing Services Global (OTCQB: SHRG), a publicly traded company specializing in direct selling and other sectors, has once again demonstrated its ability to make quick moves as market forces shift. The company has announced plans to penetrate the travel sector as consumers should be eager to travel again soon. Travel appears on the verge of a boom, and SHRG looks poised to take its share of this growth opportunity. As more and more people get the COVID-19 vaccine, businesses are trying to determine what consumer spending will look like in the future — and the outlook seems promising. The economy appears on the cusp of a major boom cycle that economists believe could last (https://ibn.fm/xpMVK). Since the beginning of the pandemic, Americans have accumulated massive reserves of excess savings, estimated by Bloomberg Economics at a staggering $1.7 trillion in January this year. Although Americans’ worries about health and safety will likely linger, there’s pent-up demand due to this enormous amount of resources. Consumer spending over the next two quarters is expected to be the strongest in the last 70 years, and leisure expenditures may lead the way. As the economy reopens, consumers are likely to binge on so-called “revenge spending” on the things they were denied over the last year, such as travel, entertainment, and dining (https://ibn.fm/wMGt3). The travel sentiment is clearly on the upswing — recent numbers released by the U.S. Travel Association show that in January 2020, 63% of Americans had plans to travel over the next six months, up from 57% in mid-December. After a year of lockdowns due to the pandemic, consumer sentiment is picking up as the rollout of the COVID-19 vaccine gathers steam across the country (https://ibn.fm/VPqUO). Air travel is surging, and hotel bookings appear to be on the path of recovery (https://ibn.fm/KrvnM). Quick to recognize market shifts as they start to emerge, SHRG is entering into the travel industry to capitalize on this swelling opportunity that is likely to endow the previously decimated travel sector. The company plans to leverage its proven business model to provide superior travel products and experiences through broad access to savings and exclusive benefits. The travel company, one of SHRG’s subsidiaries, is intended to be an exclusive travel club offering a “Passport to Happiness” to brand partners and customers. Confident that now is the most opportune time to make this strategic move, as the next months will likely see people rushing to start traveling again, Sharing Services Global appears poised to capitalize on the major shift in consumer spending. For more information, visit www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG